Fractyl Health GUTS
NASDAQ GUTS
$0.78 +0.09 (+13.85%)
At close: Aug 21, 2026 · 4:00 PM EDT

Fractyl Health (GUTS) Net Income towards Common Stockholders (2023 - 2026)

Fractyl Health's (GUTS) quarterly Net Income towards Common Stockholders came in at -$26.1 million in Q1 2026, down 10.11% YoY from -$29.1 million in Q1 2025, and up 40.23% on a QoQ basis from -$43.7 million in Q4 2025.

Fractyl Health (GUTS) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends

Fractyl Health (GUTS) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$26.1 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 10.11% year-over-year to -$26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$143.4 million (down 60.88% YoY) and the FY2025 annual result came in at -$141.0 million, down 100.13% from the prior year.
  • Net Income towards Common Stockholders rose to -$26.1 million in Q1 2026, from -$43.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.1 million in Q1 2024 to a low of -$45.6 million in Q3 2025.
  • A 4-year average of -$25.5 million and a median of -$23.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 68.71% — and 2025, when it slumped 369.16%.
  • Tracing GUTS's Net Income towards Common Stockholders over 4 years: stood at -$23.5 million in 2023, then decreased by 6.21% to -$25.0 million in 2024, then plunged by 75.12% to -$43.7 million in 2025, then soared by 40.23% to -$26.1 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$26.1 million (Q1 2026), -$43.7 million (Q4 2025), and -$45.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 Fractyl Health 123.81 Mn 123.81 Mn - -18.67 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -67.99 Mn
Mar 31, 2026 -26.13 Mn
Dec 31, 2025 -43.73 Mn
Sep 30, 2025 -45.60 Mn
Jun 30, 2025 -27.89 Mn
Mar 31, 2025 -23.74 Mn
Dec 31, 2024 -24.97 Mn
Sep 30, 2024 -23.17 Mn
Jun 30, 2024 -17.23 Mn
Mar 31, 2024 -5.06 Mn
Dec 31, 2023 -23.51 Mn
Sep 30, 2023 -20.08 Mn
Jun 30, 2023 -34.52 Mn
Mar 31, 2023 -16.17 Mn